Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm holding this long term, but with nearly 1,000,000 shares at an average of $.60 it's still upsetting to be in the red on a stock you feel is worth much more than it's currently priced. I just want to thank you for your posts and very good analysis. I find them relaxing and reassuring on these red days. I don't have anymore available cash, so it's hard to get excited about buying at a discount anymore. I wish I would have paid more attention to the charts. I was so overwhelmed at the technology and potential here I bought 250,000 on the way up at $.54 and the rest at $.62 a few weeks ago on the way down. I never thought it could go under $.40 again. Lesson learned. Thanks again!
I need a share price of $1.065 to hit a million, but hope this one goes much higher. The news was awesome yesterday! It's like watching the next big biotech company grow up right before your eyes. The increase in institutional ownership is big as well. It adds legitimacy. The company just needs to get the word out and follow through. My big investor friends have no idea what ENZC is or comprehend its potential. How do we get more eyes on the stock?
Thanks guys! I can't go above $2.00 in my IRA for now. I have no idea why, but I get an error that the sell price is to far away from the current price. I'm definitely all in on ENZC. I got some friends and coworkers in as well. I can raise the price as news is released and we drift higher, so it's all good. The ability to end many of the horrible viruses got me hooked, seems like licensing and partnerships would be potentially huge. I never gave a thought to replacing a billion dollar product line like Tami-flu. Now, after the news the other day that's on the table as well. All for $.44. Are you kidding me?
I’ve been reading the board for about a month. I started with 250,000 shares at $.54 on the way up. I added a bunch more on the way down, but too soon as it turned out. I now have 939,550 at an average of $.60. I started with about $140,000 in my retirement fund in January and got up around $633,000 when ENZC and DPLS were near their highs. This week has been a disaster, but I’ve held every share, putting most everything into ENZC as I’ve sold off others that had good gains. I thought the chart was risky, but the technology and potential to end so many deadly viruses made this the stock to buy and hold for truly life changing money. My family isn’t rich, so this matters to me and I need to be correct . I hope this post was sincere. I hate to see people getting their hopes raised and dashed throwing in the towel if this doesn’t happen for us as the stock is just starting to recover. I’ve seen the “big buys” and “huge news” posts all over on other boards and it normally doesn’t end well. I certainly haven’t seen any crazy volume or price increases. Overall, I appreciate the people on this board and the information they post. My sell order is in for $2.00 right now. That’s the largest my broker allows for this stock and that’s in case I’m working and miss a quick rise. It was there before your post. I hope what you wrote is accurate, but ENZC should be a winner regardless. The rapid rise and MM manipulation is what caused this week’s drop. Rapid gains set us up for rapid losses. Hopefully, today will start the next leg up!
DARE Price Projection from Yahoo:
With FDA approval of BV1- $12-15
If new partnership for sildenafil announced that should add a dollar or two as well.
Ovaprene good phase 3 results and FDA approval in two to three years will spike this to $100/share and it will settle somewhere in the $60-$80 range.
Now if BV1, Sildenafil Topical and Ovaprene all make it through regulatory this will be a multibillion $ company and share price $200.
$DARE Price Projection from Yahoo:
With FDA approval of BV1- $12-15
If new partnership for sildenafil announced that should add a dollar or two as well.
Ovaprene good phase 3 results and FDA approval in two to three years will spike this to $100/share and it will settle somewhere in the $60-$80 range.
Now if BV1, Sildenafil Topical and Ovaprene all make it through regulatory this will be a multibillion $ company and share price $200.
$DARE Price Projection from Yahoo:
With FDA approval of BV1- $12-15
If new partnership for sildenafil announced that should add a dollar or two as well.
Ovaprene good phase 3 results and FDA approval in two to three years will spike this to $100/share and it will settle somewhere in the $60-$80 range.
Now if BV1, Sildenafil Topical and Ovaprene all make it through regulatory this will be a multibillion $ company and share price $200.
DARE: Huge potential in medical products for women in the pipeline in Phase 2/3 testing and will move quickly with very little volume having only 26,000,000 shares available. Grants from the Gates Foundation and others to offset research and testing costs and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing and royalties to sell hormone free contraception product Ovaprene in the USA after FDA approval. They have multiple potential billion dollar products in the works. It’s a buy and hold with huge potential and limited downside from here trading at $1.13 after a recent run to $1.77 on a mere recommendation.
https://finance.yahoo.com/news/3-strong-buy-penny-stocks-193045541.html
Focused on identifying and advancing cutting-edge therapies, Daré Bioscience’s products could provide women with additional choices, improved outcomes as well as options that are easier to use. Its strong pipeline and $1.00 share price have scored it substantial praise from the pros on Wall Street.
One of these DARE bulls is Aegis Capital’s Nathan Weinstein. Citing its DARE-BV1 asset as a key component of his bullish thesis, the analyst tells investors that DARE had kicked off its pivotal trial for the candidate in patients with bacterial vaginosis (BV) earlier than he previously expected.
Speaking to the therapy’s potential, DARE-BV1 is a bio-adhesive formulation of clindamycin phosphate 2% that, in a previous proof-of-concept study, generated an 86% clinical cure rate of BV. The trial, "DARE-BVFREE", is a randomized, double-blind, placebo-controlled pivotal Phase 3, and will enroll 240 patients across multiple sites in the U.S., with the primary endpoint being clinical cure (resolution of signs and symptoms). Weinstein points out that the therapy has already been given both Fast Track and QIDP designations. “Topline data is anticipated to be released this year, and, if the study is successful, we expect an NDA application to be filed in 2021,” the analyst added.
On top of this, DARE’s pipeline features two other promising lead assets including Ovaprene, a monthly non-hormonal contraceptive, and Sildenafil Cream, designed for the treatment of female sexual arousal disorder (FSAD).
Commenting on the pipeline, Weinstein stated, “We think the diversified, women's health-focused pipeline is undervalued relative to what we view as the upside potential, given: (1) the company's proven ability to strike sizable partnership deals, (2) the uniqueness of the assets that address what we view as unmet needs in the market, (3) the appeal of having multiple shots on goal, and (4) the possibility that FSAD proves to be a larger TAM than is currently appreciated.”
If that wasn’t enough, the company is also developing a user-controlled long-acting reversible contraceptive device called DARE-LARC1, with the product already receiving funding from the Bill & Melinda Gates Foundation.
To this end, Weinstein rates DARE shares a Buy along with a $5 price target. This figure conveys his confidence in DARE’s ability to soar 403% in the coming year. (To watch Weinstein’s track record, click here)
Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that DARE is a Strong Buy. Given its $4.50 average price target, upside of 350% could be in store for investors. (See DARE stock analysis on TipRanks)
More Price Projections:
We will see $2 when they announce they have completed enrollment in DARE-BV1 (which is on Fast Track) trial, $3 - $4 when results are published, $5 with NDA filing and $8-$10 with FDA acceptance. In 2 more years it will be the same except multiply all these numbers by 10 for Ovaprene.
DARE: Huge potential in medical products for women in the pipeline in Phase 2/3 testing and will move quickly with very little volume having only 26,000,000 shares available. Grants from the Gates Foundation and others to offset research and testing costs and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing and royalties to sell hormone free contraception product Ovaprene in the USA after FDA approval. They have multiple potential billion dollar products in the works. It’s a buy and hold with huge potential and limited downside from here trading at $1.13 after a recent run to $1.77 on a mere recommendation.
https://finance.yahoo.com/news/3-strong-buy-penny-stocks-193045541.html
Focused on identifying and advancing cutting-edge therapies, Daré Bioscience’s products could provide women with additional choices, improved outcomes as well as options that are easier to use. Its strong pipeline and $1.00 share price have scored it substantial praise from the pros on Wall Street.
One of these DARE bulls is Aegis Capital’s Nathan Weinstein. Citing its DARE-BV1 asset as a key component of his bullish thesis, the analyst tells investors that DARE had kicked off its pivotal trial for the candidate in patients with bacterial vaginosis (BV) earlier than he previously expected.
Speaking to the therapy’s potential, DARE-BV1 is a bio-adhesive formulation of clindamycin phosphate 2% that, in a previous proof-of-concept study, generated an 86% clinical cure rate of BV. The trial, "DARE-BVFREE", is a randomized, double-blind, placebo-controlled pivotal Phase 3, and will enroll 240 patients across multiple sites in the U.S., with the primary endpoint being clinical cure (resolution of signs and symptoms). Weinstein points out that the therapy has already been given both Fast Track and QIDP designations. “Topline data is anticipated to be released this year, and, if the study is successful, we expect an NDA application to be filed in 2021,” the analyst added.
On top of this, DARE’s pipeline features two other promising lead assets including Ovaprene, a monthly non-hormonal contraceptive, and Sildenafil Cream, designed for the treatment of female sexual arousal disorder (FSAD).
Commenting on the pipeline, Weinstein stated, “We think the diversified, women's health-focused pipeline is undervalued relative to what we view as the upside potential, given: (1) the company's proven ability to strike sizable partnership deals, (2) the uniqueness of the assets that address what we view as unmet needs in the market, (3) the appeal of having multiple shots on goal, and (4) the possibility that FSAD proves to be a larger TAM than is currently appreciated.”
If that wasn’t enough, the company is also developing a user-controlled long-acting reversible contraceptive device called DARE-LARC1, with the product already receiving funding from the Bill & Melinda Gates Foundation.
To this end, Weinstein rates DARE shares a Buy along with a $5 price target. This figure conveys his confidence in DARE’s ability to soar 403% in the coming year. (To watch Weinstein’s track record, click here)
Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that DARE is a Strong Buy. Given its $4.50 average price target, upside of 350% could be in store for investors. (See DARE stock analysis on TipRanks)
More Price Projections:
We will see $2 when they announce they have completed enrollment in DARE-BV1 (which is on Fast Track) trial, $3 - $4 when results are published, $5 with NDA filing and $8-$10 with FDA acceptance. In 2 more years it will be the same except multiply all these numbers by 10 for Ovaprene.
Take a look at DARE. Huge potential in medical products for women in the pipeline in Phase 2/3 testing and will move quickly with very little volume having only 26,000,000 shares available. Grants from the Gates Foundation and others to offset research and testing costs and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing and royalties to sell hormone free contraception product Ovaprene in the USA after FDA approval. They have multiple potential billion dollar products in the works. It’s a buy and hold with huge potential and limited downside from here trading at $1.13 after a recent run to $1.77 on a mere recommendation.
https://finance.yahoo.com/news/3-strong-buy-penny-stocks-193045541.html
Focused on identifying and advancing cutting-edge therapies, Daré Bioscience’s products could provide women with additional choices, improved outcomes as well as options that are easier to use. Its strong pipeline and $1.00 share price have scored it substantial praise from the pros on Wall Street.
One of these DARE bulls is Aegis Capital’s Nathan Weinstein. Citing its DARE-BV1 asset as a key component of his bullish thesis, the analyst tells investors that DARE had kicked off its pivotal trial for the candidate in patients with bacterial vaginosis (BV) earlier than he previously expected.
Speaking to the therapy’s potential, DARE-BV1 is a bio-adhesive formulation of clindamycin phosphate 2% that, in a previous proof-of-concept study, generated an 86% clinical cure rate of BV. The trial, "DARE-BVFREE", is a randomized, double-blind, placebo-controlled pivotal Phase 3, and will enroll 240 patients across multiple sites in the U.S., with the primary endpoint being clinical cure (resolution of signs and symptoms). Weinstein points out that the therapy has already been given both Fast Track and QIDP designations. “Topline data is anticipated to be released this year, and, if the study is successful, we expect an NDA application to be filed in 2021,” the analyst added.
On top of this, DARE’s pipeline features two other promising lead assets including Ovaprene, a monthly non-hormonal contraceptive, and Sildenafil Cream, designed for the treatment of female sexual arousal disorder (FSAD).
Commenting on the pipeline, Weinstein stated, “We think the diversified, women's health-focused pipeline is undervalued relative to what we view as the upside potential, given: (1) the company's proven ability to strike sizable partnership deals, (2) the uniqueness of the assets that address what we view as unmet needs in the market, (3) the appeal of having multiple shots on goal, and (4) the possibility that FSAD proves to be a larger TAM than is currently appreciated.”
If that wasn’t enough, the company is also developing a user-controlled long-acting reversible contraceptive device called DARE-LARC1, with the product already receiving funding from the Bill & Melinda Gates Foundation.
To this end, Weinstein rates DARE shares a Buy along with a $5 price target. This figure conveys his confidence in DARE’s ability to soar 403% in the coming year. (To watch Weinstein’s track record, click here)
Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that DARE is a Strong Buy. Given its $4.50 average price target, upside of 350% could be in store for investors. (See DARE stock analysis on TipRanks)
More Price Projections:
We will see $2 when they announce they have completed enrollment in DARE-BV1 (which is on Fast Track) trial, $3 - $4 when results are published, $5 with NDA filing and $8-$10 with FDA acceptance. In 2 more years it will be the same except multiply all these numbers by 10 for Ovaprene.
Take a look at DARE. Huge potential in medical products for women in the pipeline in Phase 2/3 testing and will move quickly with very little volume having only 26,000,000 shares available. Grants from the Gates Foundation and others to offset research and testing costs and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing and royalties to sell hormone free contraception product Ovaprene in the USA after FDA approval. They have multiple potential billion dollar products in the works. It’s a buy and hold with huge potential and limited downside from here trading at $1.13 after a recent run to $1.77 on a mere recommendation.
https://finance.yahoo.com/news/3-strong-buy-penny-stocks-193045541.html
Focused on identifying and advancing cutting-edge therapies, Daré Bioscience’s products could provide women with additional choices, improved outcomes as well as options that are easier to use. Its strong pipeline and $1.00 share price have scored it substantial praise from the pros on Wall Street.
One of these DARE bulls is Aegis Capital’s Nathan Weinstein. Citing its DARE-BV1 asset as a key component of his bullish thesis, the analyst tells investors that DARE had kicked off its pivotal trial for the candidate in patients with bacterial vaginosis (BV) earlier than he previously expected.
Speaking to the therapy’s potential, DARE-BV1 is a bio-adhesive formulation of clindamycin phosphate 2% that, in a previous proof-of-concept study, generated an 86% clinical cure rate of BV. The trial, "DARE-BVFREE", is a randomized, double-blind, placebo-controlled pivotal Phase 3, and will enroll 240 patients across multiple sites in the U.S., with the primary endpoint being clinical cure (resolution of signs and symptoms). Weinstein points out that the therapy has already been given both Fast Track and QIDP designations. “Topline data is anticipated to be released this year, and, if the study is successful, we expect an NDA application to be filed in 2021,” the analyst added.
On top of this, DARE’s pipeline features two other promising lead assets including Ovaprene, a monthly non-hormonal contraceptive, and Sildenafil Cream, designed for the treatment of female sexual arousal disorder (FSAD).
Commenting on the pipeline, Weinstein stated, “We think the diversified, women's health-focused pipeline is undervalued relative to what we view as the upside potential, given: (1) the company's proven ability to strike sizable partnership deals, (2) the uniqueness of the assets that address what we view as unmet needs in the market, (3) the appeal of having multiple shots on goal, and (4) the possibility that FSAD proves to be a larger TAM than is currently appreciated.”
If that wasn’t enough, the company is also developing a user-controlled long-acting reversible contraceptive device called DARE-LARC1, with the product already receiving funding from the Bill & Melinda Gates Foundation.
To this end, Weinstein rates DARE shares a Buy along with a $5 price target. This figure conveys his confidence in DARE’s ability to soar 403% in the coming year. (To watch Weinstein’s track record, click here)
Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that DARE is a Strong Buy. Given its $4.50 average price target, upside of 350% could be in store for investors. (See DARE stock analysis on TipRanks)
More Price Projections:
We will see $2 when they announce they have completed enrollment in DARE-BV1 (which is on Fast Track) trial, $3 - $4 when results are published, $5 with NDA filing and $8-$10 with FDA acceptance. In 2 more years it will be the same except multiply all these numbers by 10 for Ovaprene.
DARE-Low float, huge product line of women's health products in pipeline, several in late stage testing, $320,000,000 deal with Bayer for Ovaprene (hormone free contraceptive), Gates foundation and other grants to offset testing costs, recently ran from about $1.20 to $1.77 as it was named a biotech stock that can have huge returns.
https://finance.yahoo.com/news/3-strong-buy-penny-stocks-193045541.html
Daré Bioscience, Inc. (DARE)
Focused on identifying and advancing cutting-edge therapies, Daré Bioscience’s products could provide women with additional choices, improved outcomes as well as options that are easier to use. Its strong pipeline and $1.00 share price have scored it substantial praise from the pros on Wall Street.
One of these DARE bulls is Aegis Capital’s Nathan Weinstein. Citing its DARE-BV1 asset as a key component of his bullish thesis, the analyst tells investors that DARE had kicked off its pivotal trial for the candidate in patients with bacterial vaginosis (BV) earlier than he previously expected.
Speaking to the therapy’s potential, DARE-BV1 is a bio-adhesive formulation of clindamycin phosphate 2% that, in a previous proof-of-concept study, generated an 86% clinical cure rate of BV. The trial, "DARE-BVFREE", is a randomized, double-blind, placebo-controlled pivotal Phase 3, and will enroll 240 patients across multiple sites in the U.S., with the primary endpoint being clinical cure (resolution of signs and symptoms). Weinstein points out that the therapy has already been given both Fast Track and QIDP designations. “Topline data is anticipated to be released this year, and, if the study is successful, we expect an NDA application to be filed in 2021,” the analyst added.
On top of this, DARE’s pipeline features two other promising lead assets including Ovaprene, a monthly non-hormonal contraceptive, and Sildenafil Cream, designed for the treatment of female sexual arousal disorder (FSAD).
Commenting on the pipeline, Weinstein stated, “We think the diversified, women's health-focused pipeline is undervalued relative to what we view as the upside potential, given: (1) the company's proven ability to strike sizable partnership deals, (2) the uniqueness of the assets that address what we view as unmet needs in the market, (3) the appeal of having multiple shots on goal, and (4) the possibility that FSAD proves to be a larger TAM than is currently appreciated.”
If that wasn’t enough, the company is also developing a user-controlled long-acting reversible contraceptive device called DARE-LARC1, with the product already receiving funding from the Bill & Melinda Gates Foundation.
To this end, Weinstein rates DARE shares a Buy along with a $5 price target. This figure conveys his confidence in DARE’s ability to soar 403% in the coming year. (To watch Weinstein’s track record, click here)
Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that DARE is a Strong Buy. Given its $4.50 average price target, upside of 350% could be in store for investors.
Check out DARE! Low float, huge product line of women's health products in pipeline, several in late stage testing, $320,000,000 deal with Bayer for Ovaprene (hormone free contraceptive), Gates foundation and other grants to offset testing costs, recently ran from about $1.20 to $1.77 as it was named a biotech stock that can have huge returns.
https://finance.yahoo.com/news/3-strong-buy-penny-stocks-193045541.html
Daré Bioscience, Inc. (DARE)
Focused on identifying and advancing cutting-edge therapies, Daré Bioscience’s products could provide women with additional choices, improved outcomes as well as options that are easier to use. Its strong pipeline and $1.00 share price have scored it substantial praise from the pros on Wall Street.
One of these DARE bulls is Aegis Capital’s Nathan Weinstein. Citing its DARE-BV1 asset as a key component of his bullish thesis, the analyst tells investors that DARE had kicked off its pivotal trial for the candidate in patients with bacterial vaginosis (BV) earlier than he previously expected.
Speaking to the therapy’s potential, DARE-BV1 is a bio-adhesive formulation of clindamycin phosphate 2% that, in a previous proof-of-concept study, generated an 86% clinical cure rate of BV. The trial, "DARE-BVFREE", is a randomized, double-blind, placebo-controlled pivotal Phase 3, and will enroll 240 patients across multiple sites in the U.S., with the primary endpoint being clinical cure (resolution of signs and symptoms). Weinstein points out that the therapy has already been given both Fast Track and QIDP designations. “Topline data is anticipated to be released this year, and, if the study is successful, we expect an NDA application to be filed in 2021,” the analyst added.
On top of this, DARE’s pipeline features two other promising lead assets including Ovaprene, a monthly non-hormonal contraceptive, and Sildenafil Cream, designed for the treatment of female sexual arousal disorder (FSAD).
Commenting on the pipeline, Weinstein stated, “We think the diversified, women's health-focused pipeline is undervalued relative to what we view as the upside potential, given: (1) the company's proven ability to strike sizable partnership deals, (2) the uniqueness of the assets that address what we view as unmet needs in the market, (3) the appeal of having multiple shots on goal, and (4) the possibility that FSAD proves to be a larger TAM than is currently appreciated.”
If that wasn’t enough, the company is also developing a user-controlled long-acting reversible contraceptive device called DARE-LARC1, with the product already receiving funding from the Bill & Melinda Gates Foundation.
To this end, Weinstein rates DARE shares a Buy along with a $5 price target. This figure conveys his confidence in DARE’s ability to soar 403% in the coming year. (To watch Weinstein’s track record, click here)
Turning now to the rest of the Street, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that DARE is a Strong Buy. Given its $4.50 average price target, upside of 350% could be in store for investors.
Take a look at DARE. Huge potential medical products for women in the pipeline (Phase 2/3 testing) and will move quickly with very little volume (only 24,000,000 shares). Multiple grants in the millions to cover research and testing costs without dilution of stock and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing plus royalties to sell hormone free contraception drug Ovaprene in the USA after FDA approval. Dare-BV-1 was just put on Fast Track in yesterday’s news and has a cure rate of 86% vs. current FDA approved products that range from 37-68% cure rate. Company will look to partner up with a deal similar to the Bayer deal. Stock is trading around $1.00 with potential to soar with additional grants, partnerships, and FDA approvals.
Take a look at DARE. Huge potential medical products for women in the pipeline (Phase 2/3 testing) and will move quickly with very little volume (only 24,000,000 shares). Multiple grants in the millions to cover research and testing costs without dilution of stock and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing plus royalties to sell hormone free contraception drug Ovaprene in the USA after FDA approval. Dare-BV-1 was just put on Fast Track in yesterday’s news and has a cure rate of 86% vs. current FDA approved products that range from 37-68% cure rate. Company will look to partner up with a deal similar to the Bayer deal. Stock is trading around $1.00 with potential to soar with additional grants, partnerships, and FDA approvals.
Take a look at DARE. Huge potential medical products for women in the pipeline (Phase 2/3 testing) and will move fast with very little volume (24,000,000 shares). Grants from the Gates Foundation (Total $20,000,000) and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing plus royalties to sell in the USA after FDA approval on hormone free contraception drug Ovaprene. They have multiple potential billion dollar products in the works. I bought in at $1.35, but with the recent market action you can get it today for $1.05. It’s a buy and hold with huge potential and limited downside from here. Up today despite market with solid news out on “female Viagra” product test results.
Take a look at DARE. Huge potential medical products for women in the pipeline (Phase 2/3 testing) and will move fast with very little volume (24,000,000 shares). Grants from the Gates Foundation (Total $20,000,000) and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing plus royalties to sell in the USA after FDA approval on hormone free contraception drug Ovaprene. They have multiple potential billion dollar products in the works. I bought in at $1.35, but with the recent market action you can get it today for $1.08. It’s a buy and hold with huge potential and limited downside from here. Up today despite market with solid news out on “female Viagra” product test results.
Take a look at DARE. Huge potential medical products for women in the pipeline (Phase 2/3 testing) and will move fast with very little volume (24,000,000shares). Grants from the Gates Foundation and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing plus royalties to sell in the USA after FDA approval on hormone free contraception drug Ovaprene. They have multiple potential billion dollar products in the works. I bought in at $1.35, but with the recent market action you can get it today for $1.03. It’s a buy and hold with huge potential and limited downside from here.
Take a look at DARE. Huge potential medical products for women in the pipeline (Phase 2/3 testing) and will move fast with very little volume (24,000,000shares). Grants from the Gates Foundation and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing to sell in the USA after FDA approval on hormone free contraception drug Ovaprene. They have two potential billion dollar products in the works. I bought in at $1.35, but with the recent market action you can get it today for $1.05. It’s a buy and hold with huge potential and limited downside from here.
Take a look at DARE. Huge potential medical products for women in the pipeline (Phase 2/3 testing) and will move fast with very little volume (24,000,000shares). Grants from the Gates Foundation and a sweet deal with Bayer already in place with the potential for $320,000,000 in licensing to sell in the USA after FDA approval on hormone free contraception drug Ovaprene. They have two potential billion dollar products in the works. I bought in at $1.35, but with the recent market action you can get it today for $1.05. It’s a buy and hold with huge potential and limited downside from here.
Check out MEET. Internet dating/meeting site similar to MTCH and MOMO with game changing live video chatting. Advertising revenue along with reoccurring fees. Live video revenue was $0 a year ago, now $48,000,000 annualized and still growing month over month. The stock is trading at $5.40 and setting new highs daily. It’ll likely double by the end of the year when new earnings are released and is a big time buyout candidate for MTCH. The Yahoo message board is an excellent source for DD. Huge potential winner!
Check out MEET. Internet dating/meeting site similar to MTCH and MOMO with game changing live video chatting. Advertising revenue along with reoccurring fees. Live video revenue was $0 a year ago, now $48,000,000 annualized and still growing month over month. The stock is trading at $5.40 and setting new highs daily. It’ll likely double by the end of the year when new earnings are released and is a big time buyout candidate for MTCH. The Yahoo message board is an excellent source for DD. Huge potential winner!
Check out MEET. Internet dating/meeting site similar to MTCH and MOMO with game changing live video chatting. Advertising revenue along with reoccurring fees. Live video revenue was $0 a year ago, now $48,000,000 annualized and still growing month over month. The stock is trading at $5.40 and setting new highs daily. It’ll likely double by the end of the year when new earnings are released and is a big time buyout candidate for MTCH. The Yahoo message board is an excellent source for DD. Huge potential winner!
What’s the reason for the big fall today? I saw we got some initial coverage and price targets from some analysts and they claimed this was a competitive sector, but the price targets I saw were $24, $29, and $39, so what’s the issue? I’ve got 5,000 shares of this at $22 and will look to add more if possible. I think $30 is very possible.
Freaking unbelievable! I really thought this was going to be a success when the dolls launched and early too. They had me completely fooled. Crooks! Rot in hell.
It's been a tough few months here, but this could turn on a dime with the release of some impressive sales numbers. I emailed Sarah to see if there were any plans to issue a PR on them. I'm still holding and will likely add some more if it stays down here a little longer. No reason to sell now. The potential is still there if they follow through with the plan. I like what they've been able to do in a relatively short time. The celebrities and free publicity can't hurt. I haven't seen any complaints on the dolls quality or anything to change my mind on the company.
I picked up a few at $.0026 today too. I'm not a high roller like many here, but I'm up to just under 300,000 shares now. I wish I had the cash to buy more, but I do what I can. I think this is a big winner in the making and we just need to give it time.
I just sent in a check to add a few more too. I should be good to go by Friday, so it's OK if it trades down here the rest of the week. LOL I'm sure the company is selling shares, but if it's to get the dolls to the public I'm fine with it for now. I still think there's too many positives here for this not to be a big winner. Those that are trying to make people believe it's just another share printing press forget that this company has an actual product and many on the board have bought and received it. This company is in it's infancy. It's going to be exciting to watch it and are accounts grow together. I can't wait to see where this is in 2014 and beyond. Long and strong!
Preach it! That was very well said! Please, post more often. I think most here are very positive on the stock and think it's got a great future. I hope you make the company "memorable" for all of us! I think you've got a great product and huge potential market. You just need to keep getting the word out! Good luck!
My 4 year old daughter loves the cartoons and we'll check out the new site tonight too. It goes beyond the kids. I mentioned it here before, but the minority women at work that I showed the site too love the idea and the dolls. They want them for their kids because they grew up mainly playing with white dolls that didn't look like them and it bothered them. They want them for their kids. These are going to be very well received. It's just going to take time to get the name out there. I really think if you put away 1,000,000 shares OWOO will make you a millionaire down the road. The market is there for this product! The exciting stuff hasn't even begun to happen yet. I can't afford a million shares, but I'm holding the ones I have for a minimum of 2-3 years and don't really worry about the daily ups and downs. Go OWOO!
Agreed. These guys just get it. They know how to interact with shareholders and keep them informed and know what kids like too. I have two kids and they love these interactive game sites. They are getting it done step by step. This is going to be a big winner in a year or so. I'm convinced dollar land is coming by 2014-2015. I think we'll see $.10 by the 1st quarter of 2014.
It's exciting for us. I can't imagine what it's like for them to see all of this happening seemingly overnight. I'm shocked at how quickly they are getting things done. I wish my company was this efficient and transparent! No reason to sell with the rest of the dolls, cartoon, and movie coming next year! You sell this for under $1.00 and you'll be kicking yourself for a long time.
No lie. This is a real company that gets it and continues to deliver ahead of schedule. It's really exciting to see it all start to come together. You can flip for a few bucks now or hold for serious cash when this trades in dollars! Congrats OWOO! Great weekend of free publicity on Bravo and the getting the dolls to market ahead of schedule! This is going to be huge!
I totally agree. I’ve held for 3 months now and don’t pay much attention to the daily moves. I want to keep some of this for a few years and see what it turns into down the road. I see big things for OWOO. There's nothing wrong with selling at a profit, but I think those that are willing to be patient are going to make some serious money here. These guys are good! They know what they’re doing and all have a big stake in the company. Imagine the merchandising possibilities with the dolls, celebrity dolls and endorsements, accessories, cartoons, and a movie? Look down the road and it’s not hard to see clothing, lunch boxes, back packs, and video games on top of what we know now. How much would that be worth to a Mattel if this line takes off? Plus, Stacey and others have a relationship with Mattel right now. Mark this post. This stock will trade in dollars in the next couple of years without a doubt. Patience…
They are getting things done. The dolls look great! I can't wait to get some sales figures and see where this stock is trading next year. I think the predictions of $.10 are very short term (end of 2013). We're talking about a line of 5 diverse dolls, celebrity dolls and endorsements, accessories, cartoons, a movie, and likely other apparel and toys if this takes off as I expect it to next year. I fully expect this to reach $.50 to $1.00 down the road with relative ease.
I couldn't agree more. I've been holding for 3 months and have no intention of selling this one anytime soon. The stock's having a great day, but the real fun hasn't even started yet. The word is getting out and this is going to explode towards the end of 2013 and on into 2014 when the dolls, cartoon, and movie hit. These guys are for real! I fully expect to sell this north of $.10 and I don't think $1.00 is out of the question with patience. I wish I had more free cash to add down here the last few weeks.
Welcome and wise move!
I don’t know what else you can look for in a stock trading down here. This is a fully reporting and pretty transparent company with a successful management team that came from JP Morgan and Mattel among others. They have a vision, product, and market. They may need to dilute a while longer, but dilution is fine if used properly to grow the business. I believe it’s being used to finance the doll launch, cartoon, and movie here. This has a chance to be a big winner short term ($.05 - $.10 by the end of the year) and on the big boards a few years down the road if the dolls sell which I think they will based on the opinions of everyone I’ve shown the website too. How often do you buy a stock with the type of merchandising possibilities that this one has for under $.0050? I think the dolls will be a hit and the cartoon and movie will make this a cash cow next year. What follows next could be a deal with a cartoon network, the dolls in Toys R Us, Target, and Wal-Mart... etc. Who knows? Clothing, toys, lunch boxes, backpacks, video games, etc… It’s not hard to envision this being a huge winner if all goes well. It’s worth the risk at these prices. Show me a better play under $.0050 and I'll buy it.
Wow! Exciting news! Let the games begin. Cartoon + movie = doll sales and mega merchandising oportunities! Look out above! Guys we have a big winner. Trade well, but hold some for big money! I have no doubt this will one day be traded in dollars. They have pieces of the cartoons on the website and my daughter and her friends love them and want the dolls. I ran the idea past some of the black ladies at work and they love them as well because all of the their dolls were white when they were growing up. They want them for their kids. One has even invested in OWOO. Sometimes it really is that simple! They have a huge untapped market and a quality product to fill the need. I can't wait to see where this is in a couple years.
It's good to see this one getting some attention. I've held for 2-3 months. This is a great story. Are they diluting? Yes! It's not for the reason of most stocks down here. This is not a scam. They have a product and a huge market. They need cash for the doll launch and it's coming soon. Part of the plan was to market the name and start promoting. They are following through which is great! Sarah responds to emails if you have questions. All the management folks hold a major stake here. You need to see the big picture. These are the people that have worked with some major players like Mattel. The whole management team has big company experience. The designer did a line of Barbies that was very successful in the past. They have celebrities involved as well. It goes beyond all of that though. If you look ahead I can see this being comparable to Dora or Diego. If you have kids and I have two of them, think about how many cartoons, dolls, clothes, and other merchandise those lines move. This is an easy 10 bagger around launch time. If you hold some long term it can trade in dollars down the road and a buyout candidate for someone like Mattel. Immense potential here! Go OWOO!
I'm still holding as well. I haven't gotten to add as much as I had hoped because of some health issues and medical bills with the family, but still hope to shortly. I think the company has a very bright future and sales are only a couple months away now. I can't wait to see how these dolls sell over the holidays!